Adam Kokas Insider Selling for 5,000 Shares of Atlas Air Worldwide Holdings, Inc. (AAWW); Navidea Biopharmaceuticals (NAVB)’s Sentiment Is 0.56

Navidea Biopharmaceuticals, Inc (NYSEAMERICAN:NAVB) Logo

Navidea Biopharmaceuticals Inc (NAVB) investors sentiment decreased to 0.56 in 2017 Q4. It’s down -0.80, from 1.36 in 2017Q3. The ratio worsened, as 10 investment managers started new and increased holdings, while 18 decreased and sold stock positions in Navidea Biopharmaceuticals Inc. The investment managers in our database reported: 12.03 million shares, down from 12.08 million shares in 2017Q3. Also, the number of investment managers holding Navidea Biopharmaceuticals Inc in top ten holdings was flat from 0 to 0 for the same number . Sold All: 6 Reduced: 12 Increased: 8 New Position: 2.

Lifeplan Financial Group Inc holds 0.01% of its portfolio in Navidea Biopharmaceuticals, Inc for 28,810 shares. Advisory Services Network Llc owns 5,250 shares or 0% of their US portfolio. Moreover, Ameriprise Financial Inc has 0% invested in the company for 13,600 shares. The California-based Bailard Inc. has invested 0% in the stock. Bank Of America Corp De, a North Carolina-based fund reported 37,503 shares.

The stock increased 0.11% or $0.0003 during the last trading session, reaching $0.2703. About 117,487 shares traded. Navidea Biopharmaceuticals, Inc (NAVB) has declined 36.81% since May 5, 2017 and is downtrending. It has underperformed by 48.36% the S&P500.

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company has market cap of $43.80 million. The firm develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment. It has a 0.58 P/E ratio. It is also developing NAV5001, an Iodine-123 labeled single photon emission computed tomography imaging agent that is used as an aid in the diagnosis of Parkinsons disease and other movement disorders with potential use as a diagnostic aid in dementia; diagnostic substances, including technetium 99m tilmanocept and other diagnostic applications; and therapeutic development programs, such as therapeutic applications of its Manocept platform, as well as various development programs and therapeutics.

The insider Adam Kokas who is EVP – GC & Secty. of Atlas Air Worldwide Holdings Inc unloaded 5,000 shares of the public firm having a value near $339,575 US Dollars which is based on a market stock price of $67.9 for every share. Currently, Adam Kokas owns 39,130 shares which are equivalent to precisely 0.15% of the company’s total market cap (Market Capitalization is a measurement of business value based on share price and number of shares outstanding).

Since January 2, 2018, it had 0 buys, and 11 insider sales for $3.02 million activity. Flynn William J had sold 5,000 shares worth $309,750 on Tuesday, January 16. Mayer Keith H. sold $53,298 worth of stock. $299,250 worth of Atlas Air Worldwide Holdings, Inc. (NASDAQ:AAWW) was sold by Schwartz Spencer.

Investors sentiment decreased to 1.05 in Q4 2017. Its down 0.15, from 1.2 in 2017Q3. It worsened, as 28 investors sold Atlas Air Worldwide Holdings, Inc. shares while 82 reduced holdings. 40 funds opened positions while 75 raised stakes. 35.06 million shares or 1.51% more from 34.54 million shares in 2017Q3 were reported. Sg Capital Llc has 2.1% invested in Atlas Air Worldwide Holdings, Inc. (NASDAQ:AAWW). Ngam L P accumulated 64,759 shares. 223,840 were accumulated by Smith Graham & Inv Advisors L P. Northern Trust invested 0% of its portfolio in Atlas Air Worldwide Holdings, Inc. (NASDAQ:AAWW). Wells Fargo & Mn invested in 338,534 shares. Mason Street Advsr Limited Liability Company has invested 0.01% in Atlas Air Worldwide Holdings, Inc. (NASDAQ:AAWW). Principal Fincl Gp holds 189,194 shares. Teachers Retirement Sys Of The State Of Kentucky owns 0.01% invested in Atlas Air Worldwide Holdings, Inc. (NASDAQ:AAWW) for 8,100 shares. Voya Invest Management Ltd Liability holds 438,387 shares or 0.05% of its portfolio. State Board Of Administration Of Florida Retirement System has invested 0% of its portfolio in Atlas Air Worldwide Holdings, Inc. (NASDAQ:AAWW). Legal And General Public reported 0% stake. The California-based Aperio Grp Inc Ltd Llc has invested 0% in Atlas Air Worldwide Holdings, Inc. (NASDAQ:AAWW). Bryn Mawr has 0.45% invested in Atlas Air Worldwide Holdings, Inc. (NASDAQ:AAWW) for 140,545 shares. James Inv reported 48,650 shares stake. California-based Marcato Mgmt Lp has invested 4.72% in Atlas Air Worldwide Holdings, Inc. (NASDAQ:AAWW).

More news for Atlas Air Worldwide Holdings, Inc. (NASDAQ:AAWW) were recently published by: Seekingalpha.com, which released: “Atlas Air Worldwide Holdings’ (AAWW) CEO William Flynn on Q1 2018 Results – Earnings Call Transcript” on May 03, 2018. Nasdaq.com‘s article titled: “Atlas Air Worldwide Places Second 747-400 Freighter With DHL Global Forwarding” and published on May 03, 2018 is yet another important article.

Atlas Air Worldwide Holdings, Inc., through its subsidiaries, provides outsourced aircraft and aviation operating services worldwide. The company has market cap of $1.72 billion. It operates through three divisions: ACMI, Charter, and Dry Leasing. It has a 7.77 P/E ratio. The firm offers outsourced cargo and passenger aircraft operating solutions comprising contractual service arrangements, which include the provision of aircraft to clients and value-added services, such as crew, maintenance, and insurance; and crew, maintenance, and insurance services for the customer providing aircraft.

The stock decreased 0.37% or $0.25 during the last trading session, reaching $67.15. About 292,814 shares traded or 13.72% up from the average. Atlas Air Worldwide Holdings, Inc. (NASDAQ:AAWW) has risen 13.89% since May 5, 2017 and is uptrending. It has outperformed by 2.34% the S&P500.

Navidea Biopharmaceuticals, Inc (NYSEAMERICAN:NAVB) Institutional Positions Chart